drugset
drugset / Trial / NCT05615532

A Relative Bioavailability Study of LY3209590 in Healthy Participants

NCT05615532 ↗

Phase 1 Completed 168 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelBasic science

Summary

The study will be conducted in two parts (part A and part B). The main purpose of this study is to compare the amount of LY3209590 that gets into the blood stream and how long it takes the body to get rid of it, when self-administered at different body sites, abdominal wall, upper arm and thigh (part A), when administered by two different routes of injection, subcutaneously or intravenously (part B) in healthy participants. The study may last up to 65 (part A) and 184 (part B) days, respectively.

Timeline

Start
2022-11-11
Primary completion
2023-06-28
Completion
2023-06-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Efsitora Alfa Protein / enzyme biologic — Subcutaneous

Indications

No indication recorded.